Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07339735 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4064809 in Healthy Adult Participants
A Phase 1 study of Healthy Participants, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07339735 is a Phase 1 study of Healthy Participants that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 24 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07339735, a Phase 1 study of Healthy Participants, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out how much LY4064809 gets into the blood stream and how long it takes the body to get rid of it when it is given as two formulations. For each participant, the study will last about nine weeks. Participants will remain in the clinical research center for about one month.
Conditions Studied
Interventions
- DRUG LY4064809 Test Formulation
- DRUG LY4064809 Reference Formulation
Study Locations (1)
Wisconsin
- Fortrea Clinical Research Unit Inc. - Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-01-12 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07339735
The ClinicalTrials.gov registry entry for NCT07339735 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (63% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which LY4064809 Test Formulation is the first listed.
NCT07339735 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT07339735 about?
NCT07339735 is a clinical study titled "A Study of LY4064809 in Healthy Adult Participants". The purpose of this study is to find out how much LY4064809 gets into the blood stream and how long it takes the body to get rid of it when it is given as two formulations. For each participant, the study will last about nine weeks. Participants will remain in the clinical research center for about ...
What is the current status of trial NCT07339735?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-01-12. Estimated completion is 2026-03.
What conditions does trial NCT07339735 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT07339735?
The interventions under investigation include: LY4064809 Test Formulation (DRUG), LY4064809 Reference Formulation (DRUG).
Who is sponsoring clinical trial NCT07339735?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07339735 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.